EBITDA Margin % is calculated as EBITDA divided by its Revenue. Repare Therapeutics's EBITDA for the
three
months ended in Sep. 2025 was $-0.36 Mil. Repare Therapeutics's Revenue for the
three
months ended in Sep. 2025 was $11.62 Mil. Therefore, Repare Therapeutics's EBITDA margin for the quarter that ended in Sep. 2025 was -3.08%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Repare Therapeutics EBITDA Margin % Related Terms
Repare Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Repare Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPTX vs MGNX, THAR, ANIX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Repare Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repare Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Repare Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Repare Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repare Therapeutics (RPTX) has a EBITDA Margin % of -3.08% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Repare Therapeutics and its competitors.
Is Repare Therapeutics' EBITDA Margin % too high?
Repare Therapeutics' current EBITDA Margin % is -3.08%. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' EBITDA Margin % compare to MGNX and THAR?
Repare Therapeutics' EBITDA Margin % of -3.08% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Repare Therapeutics and its competitors. Repare Therapeutics's current EBITDA Margin % is -3.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current EBITDA Margin % of -3.08%. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current EBITDA Margin % is -3.08%. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current EBITDA Margin % is -3.08% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repare Therapeutics (RPTX) Overvalued in 2026?
Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued.
The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.
Key valuation signals for RPTX:
EBITDA Margin %: -3.08%
GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score
Get the complete analysis for RPTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPTX has been successfully added to your 
